Free Trial

Denali Therapeutics (DNLI) Competitors

Denali Therapeutics logo
$13.67 +0.06 (+0.44%)
Closing price 07/30/2025 04:00 PM Eastern
Extended Trading
$13.46 -0.21 (-1.50%)
As of 05:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DNLI vs. BEAM, ROIV, LEGN, RGC, ELAN, RVMD, GRFS, NUVL, TGTX, and CRSP

Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Roivant Sciences (ROIV), Legend Biotech (LEGN), Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), Nuvalent (NUVL), TG Therapeutics (TGTX), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry.

Denali Therapeutics vs. Its Competitors

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Denali Therapeutics presently has a consensus price target of $33.71, suggesting a potential upside of 146.63%. Beam Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 141.94%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Denali Therapeutics is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
0 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
3 Strong Buy rating(s)
3.11
Beam Therapeutics
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.07

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Denali Therapeutics' return on equity of -35.90% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Denali TherapeuticsN/A -35.90% -32.41%
Beam Therapeutics -609.24%-44.24%-30.97%

In the previous week, Denali Therapeutics had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for Denali Therapeutics and 6 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 1.36 beat Beam Therapeutics' score of 0.92 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$330.53M6.01-$422.77M-$2.67-5.12
Beam Therapeutics$63.52M31.90-$376.74M-$4.61-4.37

Denali Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Summary

Denali Therapeutics beats Beam Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DNLI vs. The Competition

MetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.98B$3.03B$5.65B$9.53B
Dividend YieldN/A2.39%4.71%4.03%
P/E Ratio-5.1224.3630.2320.54
Price / Sales6.01322.48449.5898.31
Price / CashN/A42.5936.0158.40
Price / Book1.608.278.345.74
Net Income-$422.77M-$55.06M$3.25B$259.12M
7 Day Performance-4.47%-3.45%-2.17%-2.61%
1 Month Performance-2.29%13.91%7.94%8.58%
1 Year Performance-43.91%3.45%36.42%15.07%

Denali Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNLI
Denali Therapeutics
4.6683 of 5 stars
$13.67
+0.4%
$33.71
+146.6%
-43.5%$1.98B$330.53M-5.12430Positive News
Upcoming Earnings
Analyst Upgrade
BEAM
Beam Therapeutics
2.2643 of 5 stars
$20.83
-4.1%
$48.75
+134.0%
-36.2%$2.09B$63.52M-4.52510Upcoming Earnings
Gap Up
ROIV
Roivant Sciences
2.5379 of 5 stars
$11.35
-1.7%
$16.50
+45.4%
+6.8%$7.72B$29.05M-45.40860Upcoming Earnings
LEGN
Legend Biotech
3.4328 of 5 stars
$41.51
-4.3%
$73.33
+76.7%
-28.9%$7.63B$627.24M-70.352,609Positive News
RGC
Regencell Bioscience
0.2455 of 5 stars
$13.80
-8.3%
N/AN/A$7.44BN/A0.0010Positive News
ELAN
Elanco Animal Health
3.2399 of 5 stars
$14.59
-2.2%
$16.17
+10.8%
+9.5%$7.25B$4.44B19.729,000Upcoming Earnings
RVMD
Revolution Medicines
4.4525 of 5 stars
$37.26
-1.7%
$68.91
+84.9%
-18.0%$6.94B$11.58M-9.32250Upcoming Earnings
GRFS
Grifols
3.4191 of 5 stars
$10.09
-0.1%
$10.30
+2.1%
+40.0%$6.94B$7.21B8.6223,822News Coverage
Gap Up
NUVL
Nuvalent
3.3916 of 5 stars
$81.94
+0.7%
$119.60
+46.0%
+2.1%$5.88BN/A-18.6740Positive News
TGTX
TG Therapeutics
3.6285 of 5 stars
$35.99
-2.5%
$43.80
+21.7%
+88.8%$5.71B$386.39M149.96290Positive News
Upcoming Earnings
CRSP
CRISPR Therapeutics
2.4937 of 5 stars
$63.75
-1.6%
$71.31
+11.9%
+2.3%$5.51B$35M-14.10460Upcoming Earnings
Gap Up

Related Companies and Tools


This page (NASDAQ:DNLI) was last updated on 7/31/2025 by MarketBeat.com Staff
From Our Partners